Carmofur

Research use only, not for human use.

Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal Y.

Carmofur is a derivative of fluorouracil, and is an antineoplastic agent that has been used in the treatment of breast and colorectal Y. Carmofur has been known to induce leukoencephalopathy.

Real Time qPCR Cell Line:Raw264.7 Concentration:10 μM. After LPS treatment (500 ng/mL; 72 h)Incubation Time:30 min Result:Effectively reduced the mRNA expression of pro-inflammatory cytokines such as IL-1β, IL-6, iNOS, TNF-α.Western Blot Analysis Cell Line:Raw264.7 Concentration:1 μM, 3 μM, 10 μM. After LPS treatment (500 ng/mL; 72 h) Incubation Time:30 min Result:Down-regulated the expression levels of p-p65 and p-κbα proteins in a dose-dependent manner, blocking the nuclear translocation of p65.

Animal Model:Male C57BL/6J mice model of LPS-induced ALI Dosage:3 mg/kg, 10 mg/kg Administration:Oral gavage (p.o.), single dose. After LPS treatment (5 mg/kg; Tracheal perfusion, single dose)Result:Significantly inhibited MPO activity, which is a marker of neutrophil abundance.Alleviated alveolar edema and inhibited neutrophil accumulation.

HCFU

Cell Cycle/DNA Damage

DNA/RNA Synthesis

DNA/RNA Synthesis

Cancer

——

61422-45-5

257.27

C11H16FN3O3

>98% (HPLC)

Ethanol: 10 mg/mL (38.87 mM); DMSO: 52 mg/mL (202.13 mM)

O=C(N(C(N1)=O)C=C(F)C1=O)NCCCCCC

5-fluoro-N-hexyl-2,4-dioxo-3,4-dihydropyrimidine-1(2H)-carboxamide

(-20℃)

With Ice Pack

≥ 2 years